Evogene (NASDAQ:EVGN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Posted by Brian Himes on Sep 4th, 2026

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.68 and traded as low as $0.5278. Evogene shares last traded at $0.5394, with a volume of 36,427 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Report on EVGN

Evogene Stock Performance

The stock has a market capitalization of $4.71 million, a P/E ratio of -0.60 and a beta of 1.41. The business has a fifty day simple moving average of $0.54 and a 200-day simple moving average of $0.67.

Insider Buying and Selling at Evogene

In related news, Director Leon Recanati acquired 460,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average price of $0.64 per share, with a total value of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This trade represents a 52.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in EVGN. XTX Topco Ltd bought a new stake in shares of Evogene during the fourth quarter valued at approximately $25,000. Jane Street Group LLC lifted its holdings in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares in the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 36,206 shares in the last quarter. 10.40% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

(Get Free Report)

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.